Sign In
Buy CGEN
Compugen Earnings Calls
| Release date | May 18, 2026 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0800 |
| EPS Surprise | -14.29% |
| Revenue estimate | 1.572M |
| Revenue actual | 2.176M |
| Revenue Surprise | 38.47% |
| Release date | Mar 02, 2026 |
| EPS estimate | -$0.0700 |
| EPS actual | $0.600 |
| EPS Surprise | 957.14% |
| Revenue estimate | 2.159M |
| Revenue actual | 67.332M |
| Revenue Surprise | 3,018.19% |
| Release date | Nov 10, 2025 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0700 |
| EPS Surprise | 22.22% |
| Revenue estimate | 14.296M |
| Revenue actual | 1.891M |
| Revenue Surprise | -86.77% |
| Release date | Aug 06, 2025 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0800 |
| EPS Surprise | -14.29% |
| Revenue estimate | 1.469M |
| Revenue actual | 1.257M |
| Revenue Surprise | -14.45% |
Last 4 Quarters for Compugen
Below you can see how CGEN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $1.46 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0800 |
| EPS surprise | -14.29% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $1.45 |
| Aug 01, 2025 | $1.48 |
| Aug 04, 2025 | $1.46 |
| Aug 05, 2025 | $1.46 |
| Aug 06, 2025 | $1.46 |
| Aug 07, 2025 | $1.44 |
| Aug 08, 2025 | $1.50 |
| Aug 11, 2025 | $1.50 |
| Aug 12, 2025 | $1.47 |
| 4 days before | 0.690% |
| 4 days after | 0.685% |
| On release day | -1.37% |
| Change in period | 1.38% |
| Release date | Nov 10, 2025 |
| Price on release | $1.67 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0700 |
| EPS surprise | 22.22% |
| Date | Price |
|---|---|
| Nov 04, 2025 | $1.61 |
| Nov 05, 2025 | $1.64 |
| Nov 06, 2025 | $1.64 |
| Nov 07, 2025 | $1.62 |
| Nov 10, 2025 | $1.67 |
| Nov 11, 2025 | $1.72 |
| Nov 12, 2025 | $1.68 |
| Nov 13, 2025 | $1.65 |
| Nov 14, 2025 | $1.64 |
| 4 days before | 3.73% |
| 4 days after | -1.80% |
| On release day | 2.99% |
| Change in period | 1.86% |
| Release date | Mar 02, 2026 |
| Price on release | $2.25 |
| EPS estimate | -$0.0700 |
| EPS actual | $0.600 |
| EPS surprise | 957.14% |
| Date | Price |
|---|---|
| Feb 24, 2026 | $1.77 |
| Feb 25, 2026 | $1.76 |
| Feb 26, 2026 | $1.79 |
| Feb 27, 2026 | $1.81 |
| Mar 02, 2026 | $2.25 |
| Mar 03, 2026 | $2.00 |
| Mar 04, 2026 | $2.14 |
| Mar 05, 2026 | $2.05 |
| Mar 06, 2026 | $2.08 |
| 4 days before | 27.12% |
| 4 days after | -7.56% |
| On release day | -11.11% |
| Change in period | 17.51% |
| Release date | May 18, 2026 |
| Price on release | $2.86 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0800 |
| EPS surprise | -14.29% |
| Date | Price |
|---|---|
| May 12, 2026 | $2.83 |
| May 13, 2026 | $2.85 |
| May 14, 2026 | $3.03 |
| May 15, 2026 | $2.75 |
| May 18, 2026 | $2.86 |
| May 19, 2026 | $2.73 |
| May 20, 2026 | $2.71 |
| May 21, 2026 | $2.61 |
| May 22, 2026 | $2.80 |
| 4 days before | 1.06% |
| 4 days after | -2.10% |
| On release day | -4.55% |
| Change in period | -1.06% |
Compugen Earnings Call Transcript Summary of Q1 2026
Compugen reported Q1 2026 progress driven by advancing its fully owned program COM701 (anti-PVRIG) into an adaptive MAIA-ovarian maintenance trial in relapsed platinum-sensitive ovarian cancer, with active enrollment across the U.S., Israel and France and an interim median PFS analysis expected in Q1 2027. The company highlighted differentiation of COM701 biology (activity in less inflamed tumors and responses independent of PD-L1 status) and the potential for a registration path if clear PFS benefit is shown. Partnered programs remain important value drivers: AstraZeneca continues to advance rilvegostomig (Rilve) across multiple trials — AZ previously estimated >$5B peak sales potential — and Compugen is eligible for future milestones and royalties; Gilead-licensed GS-0321 (anti–IL-18 binding protein antibody) is in Phase I dose escalation and also carries milestone and royalty upside. Financially, Compugen ended Q1 2026 with ~$134.9M in cash and equivalents, expects its cash runway to fund operations into 2029 (assuming no additional inflows), reported Q1 revenue of ~$2.2M and a net loss of ~$7.7M ($0.08/share). R&D spend rose due to MAIA-ovarian activity. Management emphasized the Unigen computational discovery engine as the source of current and future assets and reiterated focus on reaching value-creating clinical milestones.
